A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group
2 King‘s College London
3 Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
4 TBIP - Biomes Tropicaux et Immuno-Pathophysiologie = Tropical Biome and ImmunoPathophysiology
5 Hospital Francisco Javier Muñiz
6 CDC - Centers for Disease Control and Prevention [Atlanta, Ga., USA]
7 UdeM - Université de Montréal
8 CDC - Centers for Disease Control and Prevention [Atlanta]
9 Centers for Disease Control and Prevention
10 Critical Path Institute [Tucson, AZ]
11 RadboudUMC - Radboud University Medical Center [Nijmegen]
12 Peking University [Beijing]
13 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
14 TIMC-TrEE - Translational microbial Evolution and Engineering
15 TIMC - Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525
16 UGA - Université Grenoble Alpes
- Fonction : Auteur
- PersonId : 1521910
- ORCID : 0000-0001-5707-528X
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
- Fonction : Auteur
Résumé
Chromoblastomycosis, an implantation mycosis, is a neglected tropical disease that causes decreased quality of life, stigma, and disability. The global burden of disease is unknown and data on disease epidemiology and outcomes are severely limited by a lack of access to needed diagnostic tools and therapeutics. The World Health Organization outlined targets for chromoblastomycosis in the Road Map for Neglected Tropical Diseases 2021–2030, but little progress has been made in initiating and implementing an effective control program globally. This lack of guiding policy and progress led to the recent formation of a Global Chromoblastomycosis Working Group which has developed a global chromoblastomycosis strategy. We describe this strategy, which outlines specific steps needed to improve technical progress, strategy and service delivery, and enablers. Clinicians, researchers, public and government officials, patients, and policy makers can align their time, expertise, and resources to improve the lives of communities affected by chromoblastomycosis through this strategy.